Meglitinides drug class for Type 2 diabetes treatment include repaglinide (Prandin) and nateglinide (Starlix) as oral diabetic medications. High fasting insulin levels and a reduction in insulin action may be present in person with Type 2 diabetes symptoms but so is absent or blunted first-phase insulin response to a meal. Most sulfonylureas (except Amaryl glimepiride) increase pancreatic beta-cell insulin secretion as well as plasma insulin concentration in people with Type 2 diabetes symptoms. But sulfonylureas oral diabetic medications fail to improve first-phase insulin release. Here comes meglitinides for Type 2 diabetes treatment. Starlix (nateglinide) and Prandin (repaglinide) as oral diabetic medications do increase first-phase insulin response, allowing to control sugar levels in blood after a meal. Both Starlix 60 mg pills and Prandin 1 mg pills are rapid-acting insulin secretagogues. When Prandin or Starlix meglitinides are taken 15 to 20 minutes before a meal, postprandial glucose excersions can be contained and minimized by this oral diabetic medications. This is important because high glucose level after a meal has been linked to cardiovascular diabetic complication.
Tag Archives: sulfonylureas
Type 2 sugar diabetes results from a combination of malfunctioning insulin action in the body, and decreased insulin production in the pancreas. Type 2 sugar diabetes symptoms is often associated with high blood cholesterol and triglycerides and high blood pressure. It is also a serious risk of development of heart attack or stroke. In the past, Type 2 sugar diabetes was much less common in children and adolescents, but now it is not true anymore. With youth obesity on the rise, Type 2 sugar diabetes quickly gain ground in that category. Obesity in young people is a major risk fact or that predispose them to Type 2 sugar diabetes.
Sulfonylureas medications for Type 2 diabetes treatment were first type two medications marketed in 1957 for type 2 diabetes treatment. The first generation sulfonylureas which are tolinase, diabinese, and orinase, can improve hyperglycemia but potential drug interactions resulting in hypoglycemia make these type 2 diabetes medications less attractive than the following second generation of sulfonylureas drugs. Glipizide and glyburide drugs were introduced in 1984, with glimepiride followed in 1996.
» Read more